- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Obesity
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.2MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 318KB)
Semaglutide – March 2022
Semaglutide: Injection 0.25 mg in 0.5 mL pre-filled single dose pen, Injection 0.5 mg in 0.5 mL pre-filled single dose pen, Injection 1.0 mg in 0.5 mg pre-filled single dose pen, Injection 1.7 mg in 0.75 mL pre-filled single dose pen, Injection 2.4 mg in 0.75 mL pre-filled single dose pen; Wegovy®
Last updated
9 September 2022
